Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1432725-24-0

Post Buying Request

1432725-24-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1432725-24-0 Usage

Description

DM-4128 is a compound with various applications across different industries, including pharmaceuticals and drug delivery systems. It is known for its unique properties that make it suitable for a range of uses.

Uses

Used in Pharmaceutical Industry:
DM-4128 is used as an impurity in the drug Tolvaptan (T536650) for the treatment of hyponatremia. As a selective, competitive arginine vasopressin V2 receptor antagonist, Tolvaptan effectively manages the condition by regulating the body's water balance.
Used in Drug Delivery Systems:
In the field of drug delivery, DM-4128 is utilized to enhance the efficacy and bioavailability of various pharmaceutical compounds. Its unique properties allow for the development of novel drug delivery systems, such as organic and metallic nanoparticles, which can improve the delivery and therapeutic outcomes of medications.

Check Digit Verification of cas no

The CAS Registry Mumber 1432725-24-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,3,2,7,2 and 5 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1432725-24:
(9*1)+(8*4)+(7*3)+(6*2)+(5*7)+(4*2)+(3*5)+(2*2)+(1*4)=140
140 % 10 = 0
So 1432725-24-0 is a valid CAS Registry Number.

1432725-24-0Downstream Products

1432725-24-0Relevant articles and documents

Characterization of the stress degradation products of tolvaptan by UPLC-Q-TOF-MS/MS

Patel, Prinesh N.,Rajesh Kumar,Gananadhamu,Srinivas

, p. 21142 - 21152 (2015)

Tolvaptan (TVT) is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia. TVT was subjected to forced degradation under hydrolysis, oxidation, dry heat and photolysis conditions, in accordance with the ICH guideline Q1A (R2). The degradation products (DPs) formed have been characterized through UPLC-PDA and UPLC-Q-TOF-MS/MS studies. The chromatographic separation was achieved on an Acquity UPLC HSS T3 column (100 × 2.1 mm, 1.7 μm) with a mobile phase containing a gradient mixture of solvents A (0.1% formic acid) and B (acetonitrile) at a flow rate of 0.3 ml min-1 at 30 °C. The detection wavelength was set at 266 nm. The drug degraded under acid hydrolysis, base hydrolysis and oxidative conditions to form a total of 7 DPs. When methanol was used as the co-solvent during stress degradation, four additional DPs were formed which were absent when acetonitrile was used as the co-solvent. Comparison of the fragmentation pattern of the DPs with that of the drug helped in the elucidation of the structures of all the degradation products. The degradation pathway of the drug was established, which was duly justified by the mechanistic explanation. The developed UPLC method was validated as per ICH guidelines.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1432725-24-0